Prelude Therapeutics (PRLD) Other Non Operating Income (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Other Non Operating Income data on file, last reported at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 50.42% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.3 million (down 47.83% YoY), and the FY2025 full-year result was $5.1 million, down 59.59% from the prior year.
• Other Non Operating Income grew to $3.8 million in Q1 2026, from $891000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $5.1 million in Q4 2024 to a low of $448000.0 in Q3 2022.
• A 5-year average of $2.3 million and a median of $2.1 million in 2024 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income jumped 2723.81% in 2022 and tumbled 82.53% in 2025, its largest moves.
• Tracing PRLD's Other Non Operating Income over 5 years: stood at $4.7 million in 2022, then dropped by 9.27% to $4.3 million in 2023, then gained by 18.49% to $5.1 million in 2024, then plunged by 82.53% to $891000.0 in 2025, then soared by 325.59% to $3.8 million in 2026.
• Business Quant data shows PRLD's Other Non Operating Income at $3.8 million in Q1 2026, $891000.0 in Q4 2025, and $693000.0 in Q3 2025.